Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
Moderna (NASDAQ:MRNA) has been ranked as the top large employer in BioSpace's 2025 Best Places to Work report for the fourth consecutive year. The recognition highlights the company's reputation and commitment to innovation. Moderna continues to invest in employee development through initiatives like its AI Academy and AI-powered tools. The company was also recently recognized in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna's focus remains on creating an environment fostering meaningful careers while pursuing its mission of delivering multiple products in the coming years.
Moderna (NASDAQ:MRNA) è stata classificata come il miglior grande datore di lavoro nel rapporto 2025 Best Places to Work di BioSpace per il quarto anno consecutivo. Questo riconoscimento sottolinea la reputazione e l'impegno dell'azienda verso l'innovazione. Moderna continua a investire nello sviluppo dei propri dipendenti attraverso iniziative come la AI Academy e strumenti supportati dall'IA. L'azienda è stata recentemente riconosciuta anche nel 2024 Top Employers Survey di Science e Science Careers per il decimo anno di fila. L'obiettivo di Moderna rimane quello di creare un ambiente che favorisca carriere significative, continuando a perseguire la propria missione di fornire più prodotti nei prossimi anni.
Moderna (NASDAQ:MRNA) ha sido clasificada como el mejor gran empleador en el informe 2025 Best Places to Work de BioSpace por cuarto año consecutivo. Este reconocimiento destaca la reputación de la empresa y su compromiso con la innovación. Moderna continúa invirtiendo en el desarrollo de empleados a través de iniciativas como su AI Academy y herramientas impulsadas por IA. La compañía también fue reconocida recientemente en la 2024 Top Employers Survey de Science y Science Careers por décimo año consecutivo. El enfoque de Moderna sigue siendo crear un entorno que fomente carreras significativas mientras persigue su misión de ofrecer múltiples productos en los próximos años.
모더나 (NASDAQ:MRNA)는 BioSpace의 2025년 최고의 일터 보고서에서 4년 연속으로 최고의 대규모 고용주로 선정되었습니다. 이 인정은 회사의 명성 및 혁신에 대한 헌신을 강조합니다. 모더나는 AI Academy와 AI 기반 도구와 같은 이니셔티브를 통해 직원 개발에 계속 투자하고 있습니다. 회사는 최근 Science 및 Science Careers의 2024년 최고의 고용주 조사에서도 10년 연속으로 인정받았습니다. 모더나는 의미 있는 경력을 조성하는 환경을 만드는 데 계속 집중하고 있으며, 앞으로 몇 년 안에 여러 제품을 제공하겠다는 사명을 추구하고 있습니다.
Moderna (NASDAQ:MRNA) a été classée comme le meilleur grand employeur dans le rapport 2025 Best Places to Work de BioSpace pour la quatrième année consécutive. Cette reconnaissance met en évidence la réputation de l'entreprise et son engagement envers l'innovation. Moderna continue d'investir dans le développement des employés à travers des initiatives telles que son AI Academy et des outils alimentés par l'IA. L'entreprise a également été récemment reconnue dans le 2024 Top Employers Survey de Science et Science Careers pour la dixième année consécutive. L'objectif de Moderna reste de créer un environnement favorisant des carrières significatives tout en poursuivant sa mission de fournir plusieurs produits dans les années à venir.
Moderna (NASDAQ:MRNA) wurde zum vierten Mal in Folge als bester großer Arbeitgeber im 2025 Best Places to Work-Bericht von BioSpace eingestuft. Diese Auszeichnung hebt den Ruf des Unternehmens und sein Engagement für Innovation hervor. Moderna investiert weiterhin in die Mitarbeiterentwicklung durch Initiativen wie die AI Academy und KI-gestützte Werkzeuge. Das Unternehmen wurde zudem kürzlich in der 2024 Top Employers Survey von Science und Science Careers zum zehnten Mal in Folge anerkannt. Der Fokus von Moderna bleibt darauf, ein Umfeld zu schaffen, das sinnvolle Karrieren fördert, während es seiner Mission nachgeht, in den kommenden Jahren mehrere Produkte anzubieten.
- Recognized as top employer in BioSpace ranking for 4th consecutive year
- Maintained position in Science and Science Careers' Top Employers Survey for 10th year
- Investing in workforce development through AI Academy and digital tools
- None.
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation.
"We are honored to be recognized by BioSpace as the most desirable large employer in the life sciences industry for the fourth year in a row," said Stéphane Bancel, Chief Executive Officer of Moderna. "I am proud of the company we are building and the investments we have made in our team. We remain focused on creating an environment where employees can have meaningful careers, and where curiosity, purpose and innovation drive our mission for patients."
Moderna is aiming to deliver multiple products in the next few years, an effort that requires a highly skilled and adaptable workforce. The Company has continued to invest in learning opportunities and digital technology to accelerate innovation, such as Moderna's AI Academy and AI-powered tools. The BioSpace recognition comes shortly after Moderna was ranked in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year.
"By integrating people, culture and AI, we are building a highly innovative workforce," said Tracey Franklin, Chief People and Digital Technology Officer of Moderna. "Our people remain as bold and relentless as ever, pushing the boundaries of what's possible in healthcare to deliver life-changing medicines. I look forward to what we will accomplish next."
About Best Places to Work
Nominations for Best Places to Work opened in June 2024. Voting was conducted in August 2024. BioSpace reviewed the votes and rankings submitted by more than 3,000 life sciences professionals. Respondents were asked to identify their top three most desirable biopharma companies, segmented by large (more than 1,000+ employees) and small (less than 1,000 employees) companies. Respondents were also asked to rate their top choice organization on attributes including compensation, innovation, career growth opportunities, leadership, culture, diversity, equity and inclusion, reputation, and flexibility and remote work.
To view the complete list of BioSpace's 2025 Best Places to Work, visit: https://www.biospace.com/best-places-to-work
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's ability to deliver multiple products in the next few years. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
###
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
FAQ
What ranking did Moderna (MRNA) achieve in BioSpace's 2025 Best Places to Work report?
How many consecutive years has Moderna (MRNA) been ranked in Science and Science Careers' Top Employers Survey?
What employee development initiatives is Moderna (MRNA) implementing?
